Glypican-3 expression in wilms tumor and hepatoblastoma

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 8, 2001, Pages 496-499

  Toretsky, Jeffrey A ^a   Zitomersky, Naamah L ^a   Eskenazi, Allen E ^a   Voigt, Roger W ^a   Strauch, Eric D ^a   Sun, Chem Chih ^a   Huber, Reed ^b   Meltzer, Steven J ^a   Schlessinger, David ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Glypican 3; Hepatoblastoma; Insulin like growth factor 2; Wilms tumor

Indexed keywords

GENE PRODUCT; GLYPICAN; GLYPICAN 3; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CARCINOGENESIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; INFANT; MALE; NEPHROBLASTOMA; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ADOLESCENT; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; DNA PRIMERS; FEMALE; GLYPICANS; HEPARAN SULFATE PROTEOGLYCANS; HEPATOBLASTOMA; HUMANS; INFANT; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MALE; NEOPLASM PROTEINS; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; WILMS TUMOR;

EID: 0035199390     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200111000-00006     Document Type: Article

References (13)

1. Mast AE, Higuchi DA, Huang ZF, et al. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J 1997; 327: 577-83.
2. Song HH, Shi W, Filmus J. OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem 1997; 272: 7574-7.
3. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996; 12: 241-7.
4. Pellegrini M, Pilia G, Pantano S, et al. Gpc3 expression correlates with the phenotype of the Simpson-Golabi-Behmel syndrome. Dev Dyn 1998; 213: 431-9.
5. Weksberg R, Squire JA. Molecular biology of Beckwith-Wiedemann syndrome. Med Pediatr Oncol 1996; 27: 462-9.
6. Weidle B, Orstavik KH. Simpson-Golabi-Behmel syndrome. A new overgrowth syndrome with increased risk of tumor development. Tidsskr Nor Laegeforen 1998; 118: 1556-8.
7. Lapunzina P, Badia I, Galoppo C, et al. A patient with Simpson-Golabi-Behmel syndrome and hepatocellular carcinoma. J Med Genet 1998; 35: 153-6.
8. Schneid H, Seurin D, Vazquez MP, et al. Parental allele specific methylation of the human insulin-like growth factor II gene and Beckwith-Wiedemann syndrome. J Med Genet 1993; 30: 353-62.
9. Ward A. Beck-Wiedemann syndrome and Wilms tumor. Mol Hum Reprod 1997; 3: 157-68.
10. Toretsky JA, Helman LJ. Involvement of IGF-II in human cancer. J Endocrinol 1996; 149: 367-72.
11. Lin H, Huber R, Schlessinger D, et al. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999; 59: 807-10.
12. Gonzalez AD, Kaya M, Shi W, et al. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 1998; 141: 1407-14.
13. Huber R, Crisponi L, Mazzarella R, et al. Analysis of exon/intron structure and 400 kb of genomic sequence surrounding the 5-promoter and 3-terminal ends of the human glypican 3 (GPC3) gene. Genomics 1997; 45: 48-58.